Results 81 to 90 of about 4,861,637 (146)

Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy

Advances in Radiation Oncology
Purpose: Antibody drug conjugates (ADCs) are an increasingly important class of therapeutics among patients with breast, lung, urothelial, and other malignancies.
Emily S. Lebow, MD, Jordan Eichholz, MS, Zhigang Zhang, PhD, Nicolas Toumbacaris, MSPH, Brandon Imber, MD, MA, Linda Chen, MD, Quincey LaPlant, MD, PhD, Josh Yamada, MD, Luke R.G. Pike, MD, DPhil, Shanu Modi, MD, Andrew D. Seidman, MD, Kathryn Beal, MD, Nelson S. Moss, MD, Yao Yu, MD   +13 more
doaj   +1 more source

Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy

International audienceGynecologic malignancies have undergone significant therapeutic advances with the introduction of targeted agents such as bevacizumab and poly(ADP-ribose) polymerase inhibitors (PARPis), immune checkpoint inhibitors, and, more ...
Durante, Stefano, Colombo, Nicoletta, Fagotti, Anna, Ray-Coquard, Isabelle, Caruso, Giuseppe, Lazzari, Roberta, Casaccia Giordano, Filippo, Jereczek-Fossa, Barbara Alicja, Macchia, Gabriella, Marchetti, Claudia   +9 more
core   +1 more source

Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. [PDF]

Br J Radiol, 2022
Xu D, Yu F, Guo T, Zhou Y, Zhang J, Li Y, Jiang S, Mao J, Yang X, Chu L, Chu X, Wang S, Ni J, Zhu Z.   +13 more
europepmc   +1 more source

Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer: a retrospective cohort study

Cancer Treatment and Research Communications
Introduction: Patients with metastatic breast cancer (MBC) typically receive palliative systemic therapy until unmanageable toxicity or progression, at which point treatment is changed.
Cornelia A.M. Almekinders, Tess I.M. Snellen, Annemiek van Ommen-Nijhof, Tessa G. Steenbruggen, Elisabeth G. Klompenhouwer, Niels F.M. Kok, Koert F.D. Kuhlmann, Frederieke van Duijnhoven, Monique E.M.M. Bos, Terry G. Wiersma, Vincent O. Dezentjé, Gabe S. Sonke   +11 more
doaj   +1 more source

Fifth disease (slapped cheek syndrome)

, 2015
What is fifth disease Fifth disease, which is also known as ?slapped cheek syndrome? or erythema infectiosum is a common viral infection caused by parvovirus B19.
Centre for Disease Control
core  

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Background: About 15–20 % of patients with metastatic breast cancer (mBC) can experience oligoprogressive disease (OPD) in ≤ 5 sites of disease. Patients with OPD may benefit from metastasis-directed stereotactic radiotherapy (SBRT) to all sites of ...
Carnevale Schianca, Ambra, Giordano, Elisa, Leonardi, Maria Cristina, Santoro, Celeste, Curigliano, Giuseppe, Battaiotto, Elena, Dellapasqua, Silvia, Criscitiello, Carmen, Jereczek-Fossa, Barbara Alicja, Munzone, Elisabetta, Bianco, Nadia, Valenza, Carmine, Trapani, Dario, Milano, Monica, Taurelli Salimbeni, Beatrice, Ferrari, Annamaria, Colleoni, Marco, Dicuonzo, Samantha, Castellano, Grazia, Gandini, Sara, Katrini, Jalissa   +20 more
core   +1 more source

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. [PDF]

Cancer Sci, 2020
Kagawa Y, Furuta H, Uemura T, Watanabe N, Shimizu J, Horio Y, Kuroda H, Inaba Y, Kodaira T, Masago K, Fujita S, Niimi A, Hida T.   +12 more
europepmc   +1 more source

Efficacy and Safety of Metastatic Directed Treatment of Oligometastatic Disease: Results of a Meta-analysis

Advances in Radiation Oncology
Purpose: In patients with oligometastatic disease (OMD), local therapy to metastatic sites has gained acceptance despite uncertainty regarding its long-term benefits or whether some subgroups would benefit more than others.
Yael Berner-Wygoda, MA, MD, Eitan Amir, MB ChB, PhD, Philip Blumenfeld, MD, Meredith Li, MD, Diego Malon, MBA, MD, Neha Pathak, MD, Jacqueline Savil, MN-RN, Yonaton Zarbiv, MD, Vikaash Kumar, MD   +8 more
doaj   +1 more source

Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study

Technology in Cancer Research & Treatment
Background Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations. The optimal treatment strategy after resistance
Xinyue Li, Kaibo Ding, Dujiang Liu, Ruiqi Song, Zhongsheng Peng, Yanjun Xu, Yi Lu   +6 more
doaj   +1 more source

Outcomes of Radiotherapy in Oligoprogressive Breast Cancer

Introduction: Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario.
Silvia Chiesa, Angela Bucaro, Armando Orlandi, Cynthia Aristei, Emilio Bria, Alejandro M. Sanchez, Gianluca Franceschini, Giovanna Garufi, Fabio Marazzi, Riccardo Masetti, Calogero Casa, Vincenzo Valentini, Valeria Masiello, Alba Di Leone, Maria A. Gambacorta, Alessandra Fabi, Giampaolo Tortora, Luca Tagliaferri, Francesca Moschella, Flavia De Lauretis, Ciro Mazzarella, Niccolo Borghesan   +21 more
core   +1 more source